

1 **Evaluation of high-throughput SARS-CoV-2 serological assays in**
2 **a longitudinal cohort of mild COVID-19 patients: sensitivity,**
3 **specificity and association with virus neutralization test**

4 Antonin Bal^{1,2}, Bruno Pozzetto^{3,4}, Mary-Anne Trabaud¹, Vanessa Escuret^{1,2}, Muriel
5 Rabilloud^{5,6}, Carole Langlois-Jacques^{5,6}, Adèle Paul^{7,8}, Nicolas Guibert^{7,8}, Constance
6 D'Aubarede-Frieh^{7,8}, Amélie Massardier-Pilonchery^{7,8}, Nicole Fabien⁹, David Goncalves⁹,
7 André Boibieux¹⁰, Florence Morfin-Sherpa^{1,2}, Virginie Pitiot⁸, François Gueyffier^{6,11}, Bruno
8 Lina^{1,2}, Jean-Baptiste Fassier^{7,8}, Sophie Trouillet-Assant² COVID SER STUDY GROUP

9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon,
11 France

12 ²CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,
13 U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon,
14 France

15 ³GIMAP EA 3064 (Groupe Immunité des Muqueuses et Agents Pathogènes), Université Jean
16 Monnet, Lyon University, Saint-Etienne, France

17 ⁴Laboratory of Infectious Agents and Hygiene, University Hospital of Saint-Etienne, Saint-
18 Etienne, France

19 ⁵Université de Lyon, F-69000, Lyon, France; Université Lyon 1, F-69100, Villeurbanne,
20 France; Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et
21 Bioinformatique, F-69003, Lyon, France

22 ⁶CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
23 Equipe Biostatistique-Santé, 69100, Villeurbanne, France.

24 ⁷Lyon University, Université Claude Bernard Lyon1, Ifsttar, UMRESTTE, UMR T_9405, 8
25 avenue Rockefeller Lyon, France

26 ⁸Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France.

27 ⁹Immunology Department, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite,
28 France.

29 ¹⁰Infectious Diseases Department, Hospices Civils de Lyon, Lyon, France.

30 ¹¹Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.

31
32 **Corresponding author:** Dr Sophie Trouillet-Assant, Ph.D

33 Hospices Civils de Lyon, France

34 Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm,U1111,
35 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007, Lyon, France

36 Phone: + 33 (0)472678780 Email: sophie.assant@chu-lyon.fr

37 **Keywords:** COVID-19; SARS-CoV-2; Serological assays; Virus neutralization; Health-care
38 workers

39 **Running title:** Performance of SARS-CoV-2 serological assays

40 **Background:** The association between SARS-CoV-2 commercial serological assays and
41 virus neutralization test (VNT) has been poorly explored in mild COVID-19 patients.

42 **Methods:** A total of 439 serum specimens were longitudinally collected from 76 healthcare
43 workers with RT-PCR-confirmed COVID-19. The sensitivity (determined weekly) of nine
44 commercial serological assays were evaluated. Specificity was assessed using 69 pre-
45 pandemic sera. Correlation, agreement and concordance with the VNT were also assessed on
46 a subset of 170 samples. Area under the ROC curve (AUC) was estimated at several
47 neutralizing antibody titers.

48 **Results:** The Wantai Total Ab assay targeting the receptor binding domain (RBD) within the
49 S protein presented the best sensitivity at different times during the course of disease. The
50 specificity was greater than 95% for all tests except for the Euroimmun IgA assay. The
51 overall agreement with the presence of neutralizing antibodies ranged from 62.2% (95%CI;
52 56.0-68.1) for bioMérieux IgM to 91.2% (87.0-94.2) for Siemens. The lowest negative
53 percent agreement (NPA) was found with the Wantai Total Ab assay (NPA 33% (21.1-48.3)).
54 The NPA for other total Ab or IgG assays targeting the S or the RBD was 80.7% (66.7-89.7) ,
55 90.3 (78.1-96.1) and 96.8% (86.8-99.3) for Siemens, bioMérieux IgG and DiaSorin,
56 respectively. None of commercial assays have sufficient performance to detect a neutralizing
57 titer of 80 (AUC<0.76).

58 **Conclusions:** Although some assays presented a better agreement with VNT than others, the
59 present findings emphasize that commercialized serological tests including those targeting the
60 RBD cannot substitute a VNT for the assessment of functional antibody response.

61 **Introduction**

62 The evaluation of the humoral immune response to SARS-CoV-2 with serological tests is
63 crucial to further manage the coronavirus disease 2019 (COVID-19) pandemic. Serological
64 testing represents an easy to implement and cost-effective method allowing to rapidly identify
65 individuals exposed to the virus (1,2). Over the last few months, a large number of SARS-
66 CoV-2 commercial assays have been evaluated for their ability to detect specific antibodies
67 (3–9). However, the detection of specific SARS-CoV-2 antibodies does not indicate whether
68 or not the antibodies are functional for neutralizing the virus. In association with the
69 assessment of other immune responses, such as cellular immunity, the exploration of the
70 neutralizing antibody response is important to evaluate the protective immunity to SARS-
71 CoV-2 after infection and therefore the risk of reinfection (10–13). To date, the association
72 between SARS-CoV-2 commercial assay results and the presence of neutralizing antibodies
73 has been mainly explored in hospitalized COVID-19 patients (14–18). As conflicting findings
74 were reported, it is unclear whether the commercial serological assays would be useful to
75 assess the protective immunity against SARS-CoV-2.

76 Virus neutralization test (VNT) is considered as the reference to assess the functional ability
77 of antibodies to block the entry of the virus into human cells (19). However, such an assay
78 requires living virus manipulated in a biosafety level 3 (BSL3) facility that needs trained staff
79 and specific equipment, and which is a tedious and time-consuming method. The first study
80 exploring the association of commercial serological assays and VNT claimed that the Wantai
81 Total Ab assay detecting total antibodies directed against the SARS-CoV-2 receptor binding
82 domain (RBD) had the best characteristics to detect functional antibodies at different stages
83 and severity of disease (14). The RBD, within the sub-unit S1 of the spike protein, enables the
84 viral entry into human cells by fixing to the angiotensin-converting enzyme 2 (ACE2)
85 receptor (20). As emphasized by the authors (14), there is an urgent need for further studies

86 addressing the performance of alternative high-throughput assays in correlation with VNT
87 among persons with mild COVID-19 which is the most common form of the disease.

88 Thus, the aim of the present study was to evaluate widely-used SARS-CoV-2 serological tests
89 and their potential association with VNT in a cohort of mild COVID-19 patients.

90 **Methods**

91 **Study design and sample collection**

92 A prospective longitudinal cohort study was conducted at the laboratory associated with the
93 National reference center for respiratory viruses (University Hospital of Lyon, France)(21).
94 Healthcare workers (HCW) with symptoms suggesting a SARS-CoV-2 infection requiring a
95 RT-PCR test were included (visit 1, V1). Clinical data including date of symptom onset were
96 recorded for all included HCWs using an eCRF by trained clinical research associate. Patients
97 with a positive RT-PCR result at inclusion (V1) returned weekly for 6 additional visits (V2
98 toV7). Serum samples were collected at each visit. Written informed consent was obtained
99 from all participants; ethics approval was obtained from the national review board for
100 biomedical research in April 2020 (*Comité de Protection des Personnes Sud Méditerranée I*,
101 Marseille, France; ID RCB 2020-A00932-37), and the study was registered on
102 ClinicalTrials.gov (NCT04341142). A total of 439 serum specimens were longitudinally
103 collected from 76 HCW. Among them, 74 had mild COVID-19 related symptoms (fever,
104 cough, loss of taste or smell, diarrhea etc) and did not require hospital admission. Two out of
105 76 HCW were admitted to the hospital (not in intensive care unit, ICU) due to the severity of
106 their symptoms. Among the 439 collected samples, 170 of them taken at V2, V4, V7 from 57
107 patients were tested by VNT (for one patient the sample at V7 was missing). To compare
108 neutralizing antibody titers between mild and severe COVID-19 patients, 117 sera collected
109 longitudinally from 44 severe COVID-19 patients admitted to ICU were also tested by VNT.

110

111 In addition, to evaluate specificity we selected retrospectively 69 sera collected (before
112 August 2019) from 30 healthy volunteers, 30 patients with autoimmune diseases, and 9
113 patients with a positive serological results for *M. pneumoniae*.

114 **Virological investigation**

115 COVID-19 diagnosis at inclusion was performed by RT-PCR on nasopharyngeal swab using
116 the cobas SARS-CoV-2 assay (Roche, Basel, Switzerland).

117 A total of 9 serological assays (Abbott, DiaSorin, Siemens, Bio-Rad, Wantai Total and IgM,
118 bioMérieux IgG and IgM, Euroimmun IgA) were investigated according to the protocol
119 recommended by each manufacturer (characteristics are summarized in Table 1). Positivity
120 was established according to threshold value recommended by each manufacturer.

121 A plaque reduction neutralization test (PRNT) was used for the detection and titration of
122 neutralizing antibodies, as previously described (22). Briefly, a ten-fold dilution of each
123 serum specimen in culture medium (Dulbecco's Modified Eagle Medium containing
124 antibiotics and 2% foetal calf serum) was first heated for 30 min at 56°C to avoid
125 complement-linked reduction of the viral activity. Serial two-fold dilutions (tested in
126 duplicate) of the serum specimens in culture medium were mixed at equal volume with the
127 live SARS-CoV2 virus. After gentle shaking and a contact of 30 minutes at room temperature
128 in plastic microplates, 150 µL of the mix was transferred into 96-well microplates covered
129 with Vero E6 cells. The plates were incubated at 37°C in a 5% CO₂ atmosphere. The reading
130 was evaluated microscopically 5 to 6 days later when the cytopathic effect of the virus control
131 reached 100 TCID₅₀/150 µL. Neutralization was recorded if more than 50% of the cells
132 present in the well were preserved. The neutralizing titer was expressed as the inverse of the
133 higher serum dilution that exhibited neutralizing activity; a threshold of 20 was used (PRNT₅₀

134 titer ≥ 20). All experiments were performed in a BSL3 laboratory. The comparison of this
135 VNT with a standardized assay using retroviruses pseudo-typed with the SARS-CoV-2 S viral
136 surface protein found a high correlation and concordance (22).

137 **Statistical analyses**

138 For each test the clinical sensitivity was estimated weekly after symptom onset considering
139 SARS-CoV-2 RT-PCR results as the gold standard.

140 Regarding VNT, the overall, positive and negative percent agreements (OPA, PPA, NPA)
141 were determined for each commercial serological assay as previously described (23). The
142 correlation and concordance with the VNT were assessed using the Spearman and Cohen's
143 Kappa coefficients, respectively. The concordance was classified as slight (Cohen's Kappa
144 coefficient, [0-0.2]), fair [0.21-0.4], moderate [0.41-0.6], substantial [0.61-0.8], and almost
145 perfect [0.81-1] according to Landis and Koch criteria (24). The Cohen's Kappa coefficient
146 was not interpreted if the sensitivity was 100%. The estimation of the correlation coefficient
147 was not performed due to an upper limit of signal to cut-off ratio for the Siemens and Bio-Rad
148 assays. Specificity was assessed with 69 pre-pandemic serum specimens collected in 2019.
149 The estimates are given with their bilateral 95% confidence interval (CI) calculated using the
150 Wilson method. The 95% CI for Cohen's Kappa coefficient was calculated using the
151 bootstrap percentile method. The paired comparison of sensitivity between two assays was
152 performed with the non-parametric McNemar test. The area under the ROC curve (AUC) was
153 estimated to assess the overall performance of serological assays to detect the presence of
154 neutralizing antibodies ($\text{PRNT}_{50} \geq 20$) or higher neutralizing antibody titers ($\text{PRNT}_{50} \geq 80$).
155 Statistical analyses were carried out using SAS software, version 9.4 (Copyright (c) 2002-
156 2003 by SAS Institute Inc., Cary, NC, USA.) and R software, version 3.6.1 (R Foundation for

157 Statistical Computing, Vienna, Austria). A p-value < 0.05 was considered as statistically
158 significant.

159 **Results**

160 **Sensitivity and specificity**

161 During the first week after the onset of symptoms the sensitivity for the detection of SARS-
162 CoV-2 antibodies ranged from 6.6% (DiaSorin, Liaison) to 25.0% (Euroimmun IgA). The
163 second week the sensitivity was greater than 70% for three tests including Bio-Rad, Wantai
164 Total Ab, and Euroimmun IgA assays (74.2%, 79.0% and 72.6%, respectively). The highest
165 of sensitivity was found at week # 3 for Bio-Rad (96.6%), Wantai Total Ab (100%), Wantai
166 IgM (94.9%), bioMérieux IgM (78.0%) and Euroimmun IgA (96.6%), at week # 4 for Abbott
167 (93.2%), and at week # 6 for DiaSorin (93.2%), Siemens (98.3%) and bioMérieux IgG
168 (94.9%). After this point, a decrease of sensitivity was noted for all assays except for the
169 Wantai Total Ab which remained steady at 100% over the course of the disease (Table 1).
170 The Wantai Total Ab assay had a significantly higher sensitivity before 14 days post-
171 symptom onset with all other assays, except with the Euroimmun IgA and Bio-Rad assays;
172 after 14 days post-symptom onset, the differences were significant with all other assays.

173 In addition, we evaluated the specificity using 69 pre-pandemic sera. No false positive result
174 was found with the two Wantai assays, bioMérieux IgG, and Siemens assays. For the other
175 assays tests, the specificity was higher than 95% except for the Euroimmun IgA assay
176 (84.06%, 95%CI [72.84-91.40]). Supplementary Table 1).

177 **Kinetics of neutralizing antibody titers**

178 The neutralizing capacity of antibodies was determined at three time points for 57 patients
179 (n=170 samples, Figure 1). No neutralizing antibodies were detected in 42.0% (21/50), 5.8%
180 (3/51), and 8.7% (6/69) of samples collected between, respectively, 1-14, 15-28, and more
181 than 28 days after symptom onset. Of note, three out of 57 patients had no neutralizing
182 antibodies throughout their follow-up.

183 For comparison, we also determined the titers of neutralizing antibodies in sera longitudinally
184 collected from COVID-19 patients (n=44) admitted to an ICU (n=117 samples, Figure 1).
185 Only one patient had no neutralizing antibodies throughout follow-up (until 45 days post
186 symptoms). No neutralizing antibodies were detected in 42.3% (11/26), 2.3% (1/44), and
187 2.1% (1/47) of samples collected between, respectively, 1-14, 15-28, and more than 28 days
188 after symptom onset.

189 For the samples with a detection of neutralizing antibody (n=140 and n=104 for mild and
190 severe COVID-19 patients, respectively), the median [IQR] titer was 60 [40-100] vs 160 [80-
191 320] between 1-14 days post symptom, reached 80 [60-120] vs 480 [240-640] between 15-28
192 days post symptom and decreased in samples collected after more than 28 days (median: 60
193 [40-120] vs 320 [120-640]).

194 **Comparison of results between commercial kits and VNT**

195 The Spearman coefficient [95%CI] assessing correlation between commercial kits and VNT
196 varied from 0.43 [0.27-0.56] to 0.61 [0.49-0.71] (Figure 2, Table 2).

197 A slight and fair concordance with VNT were noticed for the 2 IgM assays evaluated herein
198 (Kappa [95%CI]: 0.24 [0.14-0.36] for bioMérieux IgM and 0.40 [0.21-0.58] for the Wantai
199 IgM assays). Regarding total Ab or IgG assays targeting the S protein, three had substantial
200 concordance with VNT (Kappa [95%CI]: 0.71[0.57-0.84] for bioMérieux, 0.70 [0.56-0.83]
201 for DiaSorin, and 0.72 [0.55-0.85] for Siemens assays) while the concordance with the
202 Wantai Total Ab assay was moderate (0.43 [0.23-0.63]; Table 2). The OPA, assessing the
203 observed concordance between commercial serological assay and VNT confirmed that
204 noticed with Cohen's kappa. In particular, the lowest OPA was reported for the 2 IgM assays
205 and for the Wantai Total Ab assay. Moreover, the NPA with VNT ranged from 33.3% [21.1-
206 48.3] for the Wantai Total Ab assay to 96.8% [86.8-99.3] for the DiaSorin and was < 90% for

207 7/9 assays. The PPA with VNT was > 90% for all tests except the DiaSorin and the two IgM
208 based assays (Wantai and bioMérieux) (Table 2).

209 Finally, ROC curves were built to estimate the performance of each commercial serological
210 assay for detecting the presence of neutralizing antibodies ($\text{PRNT}_{50} \geq 20$). The two IgM
211 assays had the lowest AUC (0.80 for both). The AUC for the other assays found high
212 performance to predict the presence of neutralizing antibodies reaching a value ≥ 0.96 for
213 Siemens, Diasorin and bioMérieux IgG. The same methodology was applied for detecting
214 higher neutralizing antibody titers ($\text{PRNT}_{50} \geq 80$); none of these commercial assays had
215 sufficient performance ($\text{AUC} < 0.76$).

216 **Discussion**

217 In a longitudinal study of 76 HCW with RT-PCR-confirmed COVID-19, we found that the
218 Wantai Total Ab assay had the best sensitivity over the course of the disease. In particular, the
219 sensitivity reached and remained at 100% as soon as week # 3 post symptom onset. This
220 finding observed in mild COVID-19 patients is consistent with previous reports of excellent
221 sensitivity of this test notably in severe patients (3,14). Importantly, the sensitivity of the
222 commercial tests can be higher in severe patients in line with a stronger humoral immune
223 response. In particular we found lower neutralizing antibody titers in mild patients than in
224 ICU patients in the present study. These findings are highly consistent with previous studies
225 (25–28) and raise questions about protective immunity after an infection although the immune
226 response is not exclusively driven by the neutralizing antibody response. The
227 immunological correlates of protection as well as the durability of natural immunity are still
228 unknown, but mild-patients who had a low neutralizing antibody titer might be not enough
229 protected to prevent a reinfection. The occurrence of reinfections in humans has been
230 explored during a SARS-CoV-2 outbreak with a high attack rate which showed that
231 individuals with preexisting neutralizing antibodies were not infected (10). Further studies are
232 needed to investigate the correlation between neutralizing antibody titers and the risk of
233 reinfections in mild COVID-19 patients. In addition, following the FDA recommendation
234 regarding the required titer for convalescent plasma donors (titer \geq 160), the data presented
235 herein show that only few mild COVID-19 patients could be eligible. Thus, the ability of a
236 commercial test to assess the neutralizing antibody response needs to be determined. With
237 this aim, Tang et al. compared three commercial assays (Roche Total Ab, Abbott IgG, both
238 tests targeting the N protein, and Euroimmun IgG assays targeting the S protein) to VNT on
239 66 specimens (15). They found that NPA was greater than 90% for all assays only at a low
240 neutralizing titer of 20 while the NPA dramatically decreased when higher neutralizing titers

241 were used, making them imperfect proxies for neutralization. For instance, the NPA for
242 neutralizing titers was less than 60% for all 3 the assays at a cutoff of 128. Tang et al. also
243 suggested to increase the manufacturer cutoff in order to improve the NPA which can be very
244 useful in a vaccination setting or for plasma donor screening.

245 Although the study design was different, notably regarding the disease severity of the patients
246 enrolled, these findings are highly consistent with those of the present study that found the
247 lowest NPA for the Wantai Total Ab assay (33%) and a NPA below 90% for all tests except
248 for bioMérieux IgG and DiaSorin. Importantly we also found with an AUC analysis that all
249 the commercial tested performed poorly at a neutralizing antibody titer of 80.

250 Furthermore, the concordance between VNT and the Wantai Total Ab assay was only
251 moderate while the concordance was substantial with bioMérieux IgG, DiaSorin, Siemens,
252 Abbott, Euroimmun IgA and Bio-Rad. The low NPA and moderate concordance noticed for
253 the Wantai Total Ab might be partially explained by the excellent ability of this test to detect
254 RBD-specific antibodies at the very early phase of infection, irrespective of their neutralizing
255 properties in line with the delay required for antibody maturation (29). In the first study
256 comparing VNT with commercialized tests, the authors found that the Wantai Total Ab assay
257 had the best characteristics to detect functional antibodies in different stages and severity of
258 disease (14). However the median interval between the onset of symptoms and sample
259 collection was 43 days for the mild patients samples tested (n=71 samples). Thus, the
260 antibodies could be detected with both the Wantai Total Ab and the VNT assay at this time
261 explaining the high PPA values noticed (14). Herein and in other reports (15–17), high PPA
262 with VNT was also found for most of the commercial serological assays. Nevertheless, for
263 determining the presence of neutralizing antibodies in serum specimen with commercial
264 assays, the NPA should be maximized to avoid misinterpretation.

265 Furthermore, as previously reported by others (29–31), not all RBD-binding antibodies have
266 neutralizing properties which is consistent with that reported herein regarding the RBD-based
267 assays that do not have perfect concordance with VNT. Conversely, antibodies targeting a
268 region other than the S protein may have functional activity, as previously reported (19,32–
269 34). In the present study, the Abbott and Bio-Rad assays directed against the N protein
270 presented a substantial concordance with VNT. N-directed and RBD-neutralizing antibodies
271 can be produced concomitantly over the course of the disease which can also explain this
272 finding.

273 In addition to the different targeted antigens, the heterogeneity in assay performance found
274 herein could be related to various factors including the detected isotypes. Moreover, antibody
275 levels may also be very different according to the time since symptom onset and according to
276 clinical severity of the disease (25). Herein, serum samples were collected longitudinally from
277 disease diagnosis enabling to explore the early phase of the antibody response in a cohort of
278 HCW, which constitutes one of the main strength of the present study.

279 The present study does, however, have certain limitations. For instance, specificity was not
280 been extensively studied; yet the Euroimmun IgA assay seemed to have the worst specificity,
281 which is consistent with previous studies reporting a lack of specificity for this assay (5,6,14).
282 In addition, the performance of other notable commercial assays such as Euroimmun IgG or
283 Roche Ig Total were not assessed. Second, not all the samples were systematically tested by
284 VNT, in-line with the labor-intensive nature of this method. Finally, the size of the tested
285 population remains small contributing to wide CI which limits the interpretation and
286 extrapolation of the results.

287 The results presented herein confirm that, the Wantai Total Ab assay presented the higher
288 sensitivity to detect SARS-CoV-2 antibodies after exposure. For the screening of neutralizing
289 antibodies in serum specimens, optimized cut-off maximizing the NPA need to be established

290 as previously suggest for the Wantai Total Ab assay (14). However, the data presented herein
291 suggest that other tests targeting the S protein as Siemens, DiaSorin or bioMérieux IgG might
292 be more useful for this indication.

293 These tests or others cannot substitute a VNT for assessing functional antibody response;
294 neutralizing assays remain the gold standard and easy-to-use tests, such as those based on
295 pseudoviruses (6,22,35), should be developed and standardized. Furthermore, the recent
296 development of surrogate virus neutralization tests based on antibody-mediated blockage of
297 the interaction between ACE-2 receptor and the RBD is very promising as they were designed
298 in an ELISA format enabling high-throughput testing (30,36,37).

299 In conclusion, the present study provides original data concerning the performance of widely-
300 used serological tests, which could help diagnostic laboratories in the choice of a particular
301 assay according to the intended use.

302 **COVID-SER study group**

303 Adnot Jérôme, Alfaiate Dulce, Bal Antonin, Bergeret Alain, Boibieux André, Bonnet Florent,
304 Bourgeois Gaëlle, Brunel-Dalmas Florence, Caire Eurydice, Charbotel Barbara, Chiarello
305 Pierre, Cotte Laurent, d'Aubarede Constance, Durupt François, Escuret Vanessa, Fascia
306 Pascal, Fassier Jean-Baptiste, Fontaine Juliette, Gaillot-Durand Lucie, Gaymard Alexandre,
307 Gillet Myriam, Godinot Matthieu, Gueyffier François, Guibert Nicolas, Josset Laurence,
308 Lahousse Matthieu, Lina Bruno, Lozano Hélène, Makhloufi Djamila, Massardier-Pilonchéry
309 Amélie, Milon Marie-Paule, Moll Frédéric, Morfin Florence, Narbey David, Nazare Julie-
310 Anne, Oria Fatima, Paul Adèle, Perry Marielle, Pitiot Virginie, Prudent Mélanie, Rabilloud
311 Muriel, Samperiz Audrey, Schlienger Isabelle, Simon Chantal, Trabaud Mary-Anne,
312 Trouillet-Assant Sophie

313 **Acknowledgements**

314 We thank all the personnel of the occupational health and medicine department of Hospices
315 Civils de Lyon who contributed to the samples collection. We thank Lucie Charreton; Kahina
316 Saker and Khadija Sfouli for their excellent work concerning serological testing, all the
317 technicians from the virology laboratory whose work made it possible to obtain all these data,
318 as well as Amira Lachekhab and Naima Rolnin for their technical assistance. We thank
319 Karima Brahima and all members of the clinical research and innovation department for their
320 reactivity (DRCI, Hospices Civils de Lyon). We thank Philip Robinson (DRCI, Hospices
321 Civils de Lyon) for his help in manuscript preparation.

322 **Author contributor's statement**

323 All authors were involved in the analysis and interpretation of data as well as drafting the
324 manuscript or revising it critically for important intellectual content. AB, BP, VP, FG, JBF
325 and STA made substantial contributions to the conception and design of the study and
326 designed the experiments. BP performed VNT. MAT and VE performed the serological assay

327 experiments. NG, AP, CA, AMP, AB, and JBF were involved in patient care, VP performed
328 the data collection, STA, AB, MA and BP performed the data analysis. MR and CLJ
329 performed the statistical analysis. AB and STA wrote the paper, BL, BP, JBF, AP, VE and
330 MAT revised the manuscript content. All authors read and approved the final manuscript.

331 **Conflict interests statement**

332 Antonin Bal has received grant from bioMérieux and has served as consultant for bioMérieux
333 for work and research not related to this manuscript. Sophie Trouillet-Assant has received
334 research grant from bioMérieux concerning previous works not related to this manuscript.
335 The other authors have no relevant affiliations or financial involvement with any organization
336 or entity with a financial interest in or financial conflict with the subject matter or materials
337 discussed in the manuscript.

338 **Funding**

339 This research is being supported by Hospices Civils de Lyon and by Fondation des Hospices
340 Civils de Lyon.

341 **References**

- 342 1. Krammer F, Simon V. Serology assays to manage COVID-19. *Science*. 2020;368:1060–
343 1.
- 344 2. Winter AK, Hegde ST. The important role of serology for COVID-19 control. *Lancet*
345 *Infect Dis*. 2020;20:758–9.
- 346 3. Trabaud M-A, Icard V, Milon M-P, Bal A, Lina B, Escuret V. Comparison of eight
347 commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG
348 or total antibody. *J Clin Virol*. 2020;132:104613.
- 349 4. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E,
350 Vandecandelaere P, et al. Antibody response against SARS-CoV-2 spike protein and
351 nucleoprotein evaluated by 4 automated immunoassays and 3 ELISAs. *Clin Microbiol*
352 *Infect*. 2020;
- 353 5. Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, André E, et al.
354 Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun
355 IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect*. 2020;26:1082–7.
- 356 6. Meyer B, Torriani G, Yerly S, Mazza L, Calame A, Arm-Vernez I, et al. Validation of a
357 commercially available SARS-CoV-2 serological immunoassay. *Clin Microbiol Infect*.
358 2020;
- 359 7. Theel ES, Haring J, Hilgart H, Granger D. Performance Characteristics of Four High-
360 Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. *J*
361 *Clin Microbiol*. 2020;58.
- 362 8. Lisboa Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui L-P, Johnston JC, et al.
363 Diagnostic accuracy of serological tests for covid-19: systematic review and meta-
364 analysis. *BMJ*. 2020;370:m2516.
- 365 9. National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics
366 of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *Lancet*
367 *Infect Dis*. 2020;
- 368 10. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M-L, et al.
369 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during
370 a Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol*. 2020;58.
- 371 11. Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: Specificity, function,
372 durability, and role in protection. *Sci Immunol*. 2020;5.
- 373 12. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et
374 al. A systematic review of antibody mediated immunity to coronaviruses: kinetics,
375 correlates of protection, and association with severity. *Nat Commun*. 2020;11:4704.
- 376 13. Rychert J, Couturier MR, Elgort M, Lozier BK, La'ulu S, Genzen JR, et al. Evaluation
377 of Three SARS CoV-2 IgG Antibody Assays and Correlation with Neutralizing
378 Antibodies. *J Appl Lab Med*. 2020;

- 379 14. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et
380 al. An evaluation of COVID-19 serological assays informs future diagnostics and
381 exposure assessment. *Nat Commun.* 2020;11:3436.
- 382 15. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al.
383 Association between SARS-CoV-2 neutralizing antibodies and commercial serological
384 assays. *Clin Chem.* 2020;
- 385 16. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, et
386 al. Performance of six SARS-CoV-2 immunoassays in comparison with
387 microneutralisation. *J Clin Virol.* 2020;129:104512.
- 388 17. Suhandynata RT, Hoffman MA, Huang D, Tran JT, Kelner MJ, Reed SL, et al.
389 Commercial Serology Assays Predict Neutralization Activity Against SARS-CoV-2.
390 *Clin Chem.* 2020;
- 391 18. Patel EU, Bloch EM, Clarke W, Hsieh Y-H, Boon D, Eby Y, et al. Comparative
392 performance of five commercially available serologic assays to detect antibodies to
393 SARS-CoV-2 and identify individuals with high neutralizing titers. *J Clin Microbiol.*
394 2020;
- 395 19. Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other
396 Human Coronaviruses. *Trends Immunol.* 2020;41:355–9.
- 397 20. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
398 associated with a new coronavirus of probable bat origin. *Nature.* 2020;579:270–3.
- 399 21. Trouillet-Assant et al. Assessment of Serological Techniques for Screening Patients
400 Regarding COVID-19 (COVID-SER): a prospective multicentric study. *BMJ open* 2020
401 In press.
- 402 22. Legros V, Denolly S, Vogrig M, Boson B, Rigai J, Pillet S, et al. A longitudinal study
403 of SARS-CoV-2 infected patients shows high correlation between neutralizing
404 antibodies and COVID-19 severity. *medRxiv.* Cold Spring Harbor Laboratory Press;
405 2020;2020.08.27.20182493.
- 406 23. Obermeier P, Muehlhans S, Hoppe C, Karsch K, Tief F, Seeber L, et al. Enabling
407 Precision Medicine With Digital Case Classification at the Point-of-Care.
408 *EBioMedicine.* 2016;4:191–6.
- 409 24. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
410 *Biometrics.* 1977;33:159–74.
- 411 25. Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
412 Differences in antibody kinetics and functionality between severe and mild SARS-CoV-
413 2 infections. *J Infect Dis.* 2020;
- 414 26. Mehew J, Johnson R, Roberts D, Harvala H. Convalescent plasma for COVID-19: male
415 gender, older age and hospitalisation associated with high neutralising antibody levels,
416 England, 22 April to 12 May 2020. *Euro Surveill.* 2020;25.

- 417 27. Zeng C, Evans JP, Pearson R, Qu P, Zheng Y-M, Robinson RT, et al. Neutralizing
418 antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and
419 convalescent plasma donors. *JCI Insight*. 2020;
- 420 28. Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Low serum
421 neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19
422 convalescent patients revealed by two different detection methods. *Cell Mol Immunol*.
423 2020;
- 424 29. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited
425 by SARS-CoV-2 infection. *Nature*. 2020;584:115–9.
- 426 30. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate
427 virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-
428 protein interaction. *Nat Biotechnol*. 2020;38:1073–8.
- 429 31. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, et al. Serological assays for
430 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. *Euro*
431 *Surveill* [Internet]. 2020 [cited 2020 Oct 21];25. Available from:
432 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189648/>
- 433 32. Tong P-B-V, Lin L-Y, Tran TH. Coronaviruses pandemics: Can neutralizing antibodies
434 help? *Life Sci*. 2020;255:117836.
- 435 33. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.
436 *Antib Ther*. 2020;3:109–14.
- 437 34. Cohen SA, Kellogg C, Equils O. Neutralizing and cross-reacting antibodies:
438 implications for immunotherapy and SARS-CoV-2 vaccine development. *Hum Vaccin*
439 *Immunother*. 2020;1–4.
- 440 35. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a
441 pseudovirus neutralization assay for SARS-CoV-2. *Emerg Microbes Infect*. 2020;9:680–
442 6.
- 443 36. Byrnes JR, Zhou XX, Lui I, Elledge SK, Glasgow JE, Lim SA, et al. A SARS-CoV-2
444 serological assay to determine the presence of blocking antibodies that compete for
445 human ACE2 binding. *medRxiv* [Internet]. 2020 [cited 2020 Sep 29]; Available from:
446 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273274/>
- 447 37. Walker SN, Chokkalingam N, Reuschel EL, Purwar M, Xu Z, Gary EN, et al. SARS-
448 CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition
449 in Vaccinated Animals and Infected Patients. *J Clin Microbiol*. 2020;58.

450

452

Manufacturer (platform)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai		bioMérieux (Vidas®)		Euroimmun
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1

Sensitivity vs SARS-CoV-2 RT-PCR [95%CI]

days after symptom onset (n)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai (SARS-CoV-2 Total Ab)	Wantai (SARS-CoV-2 IgM)	bioMérieux (Vidas®) (SARS-CoV-2 IgG)	bioMérieux (Vidas®) (SARS-CoV-2 IgM)	Euroimmun (SARS-CoV-2 IgA)
[1-7] (61)	9.84 [5.17-17.91]	6.56 [2.98-13.83]	6.56 [2.98-13.83]	18.03 [11.35-27.43]	22.95 [15.36-32.84]	13.11 [7.55-21.81]	8.20 [4.05-15.90]	11.48 [6.34-19.88]	25.00 [17.02-35.00]
[8-14] (63)	59.68 [49.23-69.31]	32.26 [23.41-42.59]	41.94 [32.18-52.37]	74.19 [64.18-82.19]	79.03 [69.41-86.23]	64.52 [54.11-73.71]	39.68 [30.17-50.04]	49.21 [39.09-59.38]	72.58 [62.47-80.00]
[15-21] (59)	91.53 [83.60-95.81]	83.05 [73.61-89.59]	89.83 [81.52-94.65]	96.61 [90.26-98.87]	100.00 [95.62-100.00]	94.92 [87.94-97.95]	86.44 [77.50-92.19]	77.97 [67.97-85.50]	96.61 [90.26-98.87]
[22-28] (59)	93.22 [85.73-96.92]	86.44 [77.50-92.19]	93.22 [85.73-96.92]	94.92 [87.94-97.95]	100.00 [95.62-100.00]	89.83 [81.52-94.65]	93.22 [85.73-96.92]	69.49 [58.96-78.32]	91.53 [83.60-95.81]
[29-35] (65)	86.15 [77.66-91.76]	92.31 [85.03-96.21]	93.85 [86.98-97.21]	92.19 [84.81-96.15]	100.00 [96.00-100.00]	84.62 [75.89-90.58]	90.77 [83.13-95.15]	52.31 [42.23-62.20]	84.62 [75.89-90.58]
[36-42] (59)	89.83 [81.52-94.65]	93.22 [85.73-96.92]	98.31 [92.75-99.62]	91.53 [83.60-95.81]	100.00 [95.62-100.00]	88.14 [79.49-93.44]	94.92 [87.94-97.95]	45.76 [35.51-56.38]	88.14 [79.49-93.44]
[43-85] (73)	89.04 [81.58-93.71]	89.04 [81.58-93.71]	95.89 [90.15-98.35]	88.89 [81.34-93.62]	100.00 [96.38-100.00]	81.94 [73.38-88.20]	87.67 [79.97-92.68]	43.84 [34.67-53.44]	79.45 [70.69-86.00]

453 Table 1 – Sensitivity of 9 SARS-CoV-2 commercial serological assays. Positivity was established according to threshold value recommended by
454 each manufacturer. Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent assay, CMIA: chemiluminescence
455 microparticle immune assay CLIA: chemiluminescence immune assay, ELFA: enzyme-linked fluorescent assay, n: number of samples, CI:
456 confidence interval.

457
458

Manufacturer (platform)	Abbott (Architect)	DiaSorin (Liaison®)	Siemens (Atellica®)	Bio-Rad	Wantai		bioMérieux (Vidas®)		Euroimmun
Assay name	SARS-CoV-2 IgG	SARS-CoV-2 S1/S2 IgG	SARS-CoV-2 Total	Platelia SARS-CoV-2 Total Ab	SARS-CoV-2 Total Ab	SARS-CoV-2 IgM	SARS-CoV-2 IgG	SARS-CoV-2 IgM	SARS-CoV-2 IgA
Assay type	CMIA	CLIA	CLIA	ELISA	ELISA	ELISA	ELFA	ELFA	ELISA
Antigen	N	S1+S2	RBD	N	RBD	RBD	RBD	RBD	S1
Overall, Negative and Positive Percent Agreement with VNT									
OPA [95%CI]	88.9 [84.3-92.3]	89.5 [85.0-92.7]	91.2 [87.0-94.2]	89.4 [84.9-92.7]	87.7 [82.9-91.2]	81.2 [75.8-85.6]	90.1 [85.7-93.3]	62.2 [56.0-68.1]	88.3 [83.7-91.8]
NPA [95%CI]	74.2 [59.7-84.8]	96.8 [86.8-99.3]	80.7 [66.7-89.7]	61.3 [46.6-74.2]	33.3 [21.1-48.3]	56.7 [41.9-70.4]	90.3 [78.1-96.1]	83.9 [70.4-91.9]	67.7 [53.0-79.6]
PPA [95%CI]	92.1 [87.6-95.1]	87.9 [82.6-91.7]	93.6 [89.3-96.2]	95.7 [91.9-97.8]	99.3 [96.9-99.9]	86.4 [81.0-90.5]	90.1 [85.1-93.5]	57.4 [50.5-64.1]	92.9 [88.4-95.7]
OPA [95%CI] <14dps	85.4 [75.2-91.9]	68.8 [57.0-78.5]	83.3 [72.8-90.4]	85.4 [75.2-91.9]	75.0 [63.6-83.8]	81.3 [70.4-88.8]	69.4 [57.8-79.0]	75.5 [64.3-84.1]	81.3 [70.4-88.8]
OPA [95%CI] >14dps	90.0 [84.6-93.7]	97.5 [93.9-99.0]	94.2 [89.6-96.8]	91.6 [86.4-94.9]	92.4 [87.4-95.6]	83.2 [76.8-88.1]	98.3 [95.1-99.5]	58.3 [50.8-65.5]	90.8 [85.6-94.3]
Concordance with virus VNT - Cohen's Kappa coefficient [95%CI]									
Overall (n=170)	0.64 [0.49-0.79]	0.70 [0.56-0.83]	0.72 [0.55-0.85]	0.62 [0.44-0.76]	0.43 [0.23-0.63]	0.40 [0.21-0.58]	0.71 [0.57-0.84]	0.24 [0.14-0.36]	0.61 [0.43-0.76]
<14 dps	0.70 [0.45-0.88]	0.41 [0.19-0.60]	0.68 [0.45-0.84]	0.69 [0.45-0.86]	0.46 [0.21-0.67]	0.61 [0.35-0.79]	0.41 [0.29-0.76]	0.52 [0.27-0.72]	0.60 [0.35-0.79]
>14 dps	0.40 [-0.06-0.72]	0.86 [0.65-1]	0.51 [0-0.89]	0.45 [-0.05-0.79]	NA	0.08 [-0.09-0.35]	0.90 [0.71-1.00]	0.18 [0.02-0.25]	0.55 [0.06-0.81]
Correlation between Ab level and neutralizing Ab titer									
Spearman coefficient [95%CI]	0.47 [0.33-0.60]	0.53 [0.39-0.65]	NA	NA	0.56 [0.43-0.66]	0.54 [0.40-0.65]	0.61 [0.49-0.71]	0.50 [0.32-0.65]	0.43 [0.27-0.56]
Receiver operating characteristic (ROC) curves for serology assays to detect neutralizing anti-SARS-CoV-2 antibodies or detect neutralizing - AUC [95%CI]									
PRNT50 ≥ 20	0.94 [0.89-0.98]	0.96 [0.94-0.99]	0.96 [0.94-0.99]	0.85 [0.77-0.94]	0.93 [0.88-0.98]	0.80 [0.71-0.88]	0.97 [0.94-0.99]	0.80 [0.72-0.88]	0.91 [0.85-0.97]
PRNT50 ≥ 80	0.65 [0.57-0.73]	0.74 [0.66-0.81]	0.73 [0.66-0.81]	0.65 [0.58-0.72]	0.75 [0.68-0.82]	0.68 [0.60-0.76]	0.75 [0.68-0.82]	0.67 [0.58-0.75]	0.64 [0.55-0.72]

459
460
461


462 Table 2 – Association of SARS-CoV-2 commercial serological and a virus neutralization test. Ab: antibodies, Ig: immunoglobulin, ELISA:
463 enzyme-linked immunosorbent assay, CMIA: chemiluminescence microparticule immune assay CLIA: chemiluminescence immune assay,
464 ELFA: enzyme-linked fluorescent assay, n: number of samples, CI: confidence interval, dps: days post onset of symptoms, test. VNT: Virus
465 neutralization test.








466 **Figure 1 legend**

467 Kinetics of neutralizing antibody titers in mild and severe COVID-19 patients according to the post-symptom interval. Green points represent
468 mild COVID-19 patients, red points represent severe COVID-19 patients admitted to ICU, and blue points represent patients without neutralizing
469 antibodies throughout follow-up. Dotted lines correspond to the limit of quantification of neutralizing antibodies. Fit Loess curve represents local
470 polynomial regression performed using the Loess method. CI at 95% is indicated (grey area).

471 **Figure 2 legend**

472 Correlation between SARS-CoV-2 neutralizing antibody titers and antibodies level determined by SARS-CoV-2 commercial serological assays.
473 Magenta dots indicate sample collected ≤ 14 days post onset of symptoms (dps), blue dots indicate samples collected from 14-28 dps, black dots
474 indicate specimen collected more than 28 dps. Spearman correlation coefficients and 95% confidence interval are indicated. All p-values were <
475 0.001.





- 1-14 dps
- 15-28 dps
- ▲ > 28 dps